{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:06:22Z","timestamp":1791990382458,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","award":["175:1298-1304"],"award-info":[{"award-number":["175:1298-1304"]}],"id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.tjpad.2026.100507","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:17:14Z","timestamp":1770970634000},"page":"100507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lecanemab for treatment of individuals with early Alzheimer\u2019s Disease (AD) who are apolipoprotein E \u03b54 (ApoE \u03b54) non-carriers or heterozygotes"],"prefix":"10.1016","volume":"13","author":[{"given":"Richard","family":"Perry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Soto Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0568-2026","authenticated-orcid":false,"given":"Marco","family":"Bozzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Logroscino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Trafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Dhadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Kanekiyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-6672","authenticated-orcid":false,"given":"Steven","family":"Hersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0246-2511","authenticated-orcid":false,"given":"Michael","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1494-0813","authenticated-orcid":false,"given":"Lutz","family":"Froelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2026.100507_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00702-021-02449-2","article-title":"Recent update on the heterogeneity of the Alzheimer\u2019s disease spectrum","volume":"129","author":"Jellinger","year":"2022","journal-title":"J Neural Transm"},{"key":"10.1016\/j.tjpad.2026.100507_bib0002","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.tjpad.2026.100507_bib0003","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","article-title":"Designing the next-generation clinical care pathway for Alzheimer\u2019s disease","volume":"2","author":"Hampel","year":"2022","journal-title":"Nat Aging"},{"key":"10.1016\/j.tjpad.2026.100507_bib0004","unstructured":"World Health Organization. Fact sheet: dementia. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia. Accessed July 24, 2025."},{"key":"10.1016\/j.tjpad.2026.100507_bib0005","article-title":"World Alzheimer Report 2024","year":"2021","journal-title":"The State of the Art of Dementia Res: New Front"},{"key":"10.1016\/j.tjpad.2026.100507_bib0006","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer's disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100507_bib0007","unstructured":"Carnall Farrar (2024). The economic impact of dementia. Available from: https:\/\/www.carnallfarrar.com\/wp-content\/uploads\/2024\/05\/Alz-report.pdf [Accessed July 2025]."},{"key":"10.1016\/j.tjpad.2026.100507_bib0008","unstructured":"National Institute for Health and Care Excellence (2023). Potential issues and challenges in evaluation of disease-modifying dementia treatments. Available from: https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/HTA%20Lab\/HTA-lab-dmdt.pdf [Accessed July 2025]."},{"key":"10.1016\/j.tjpad.2026.100507_bib0009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease","volume":"27","author":"Huang","year":"2020","journal-title":"J Biomed Sci"},{"issue":"8 Suppl","key":"10.1016\/j.tjpad.2026.100507_bib0010","first-page":"S167","article-title":"Current and evolving treatment strategies for the Alzheimer disease continuum","volume":"26","author":"Marasco","year":"2020","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.tjpad.2026.100507_bib0011","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.tjpad.2026.100507_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2026.100507_bib0013","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2026.100507_bib0014","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100507_bib0015","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tjpad.2026.100507_bib0016","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100507_bib0017","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer's disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.tjpad.2026.100507_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032014","article-title":"Large aggregates are the major soluble a\u03b2 species in AD brain fractionated with density gradient ultracentrifugation","volume":"7","author":"Sehlin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tjpad.2026.100507_bib0019","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000316530","article-title":"Heavy-chain complementarity-determining regions determine conformation selectivity of anti-a\u03b2 antibodies","volume":"8","author":"Sehlin","year":"2011","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.tjpad.2026.100507_bib0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's Disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tjpad.2026.100507_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61691-2","article-title":"Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities","volume":"14","author":"S\u00f6derberg","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjpad.2026.100507_bib0022","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1523\/JNEUROSCI.3537-10.2010","article-title":"Amyloid \u03b2-protein dimers rapidly form stable synaptotoxic protofibrils","volume":"30","author":"O\u2019Nuallain","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.tjpad.2026.100507_bib0023","article-title":"Polymorphic structures of Alzheimer\u2019s \u03b2-amyloid globulomers","volume":"6","author":"Yu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tjpad.2026.100507_bib0024","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/msj.20160","article-title":"Amyloid-\u03b2 oligomers: possible roles as key neurotoxins in Alzheimer\u2019s disease","volume":"77","author":"Lublin","year":"2010","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.tjpad.2026.100507_bib0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JAD-130029","article-title":"Specific uptake of an amyloid-\u03b2-protofibril-binding antibody-tracer in a\u03b2pp transgenic mouse brain","volume":"37","author":"Magnusson","year":"2013","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.tjpad.2026.100507_bib0026","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-a\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100507_bib0027","article-title":"ARIA in participants treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.tjpad.2026.100507_bib0028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100507_bib0029","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer's disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100507_bib0030","article-title":"Long-term safety and efficacy of lecanemab in early Alzheimer's disease: results from the clarity AD open-label extension study","volume":"21","author":"van Dyck","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100507_bib0031","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100507_bib0032","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"Suppl 2","key":"10.1016\/j.tjpad.2026.100507_bib0033","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope: the Alzheimer\u2019s Disease Cooperative Study","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"Suppl 2","key":"10.1016\/j.tjpad.2026.100507_bib0034","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100507_bib0035","first-page":"963","article-title":"Detecting dementia with the mini-mental state examination in highly educated individuals","volume":"65","author":"O'Bryant","year":"2008","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100507_bib0036","doi-asserted-by":"crossref","first-page":"507","DOI":"10.14283\/jpad.2022.41","article-title":"Clinical trial endpoints and their Clinical meaningfulness in early stages of Alzheimer's Disease","volume":"9","author":"Cohen","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100507_bib0037","article-title":"Clinically meaningful benefit and real-world evidence in Alzheimer's disease research and care","volume":"11","author":"Perneczky","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100507_bib0038","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimers Dement"}],"updated-by":[{"DOI":"10.1016\/j.tjpad.2026.100527","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000}}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:02:23Z","timestamp":1777629743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726000312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2274580726000312"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100507","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lecanemab for treatment of individuals with early Alzheimer\u2019s Disease (AD) who are apolipoprotein E \u03b54 (ApoE \u03b54) non-carriers or heterozygotes","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100507"}}